Valeant Pharmaceuticals International, Inc. Stock Quote & Summary Data
Dynamic quotes: Off
|
ETFs with VRX as a Top 10 Holding*Sponsored by:
| Weighting | ETF Name (Symbol) | 100-Day Price Change (%) |
|---|---|---|
| 4.62% | Merrill Lynch Pharmaceutical HOLDRS (PPH) | +5.82 (14.62%) |
| 0% | Madrona International ETF (FWDI) | +2.32 (10.08%) |
|
||
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
Biovail Corporation (“Biovail”) was formed under the Business Corporations Act (Ontario) on February 18, 2000, as a result of the amalgamation of TXM Corporation and Biovail Corporation International. Biovail was continued under the Canada Business Corporations Act (the “CBCA”) effective June 29, 2005. On September 28, 2010 (the “Merger Date”), Biovail completed the acquisition of Valeant Pharmaceuticals International (“Valeant”) through a wholly-owned subsidiary pursuant to an Agreement and Plan of Merger, dated as of June 20, 2010, with Valeant surviving as a wholly-owned subsidiary of Biovail (the “Merger”). In connection with the Merger, Biovail was renamed “Valeant Pharmaceuticals International, Inc.” The accompanying financial statements reflect Biovail’s stand-alone operations as they existed prior to the completion of the Merger. ... More ...
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $4.4 |
| Quarterly EPS Est: | 1.28 |
| PEG Ratio: | .73 |
|
Mean Recommendation: View Summary / View All |
1.71 |
Data is provided by Zacks Investment Research